---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-25-000103"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T01:02:11.547621+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q3 revenue $205.7M (-4% YoY); GAAP net loss $0.29/sh, adj EPS $0.00; FY guidance reiterated

## Summary
- Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M in headwinds from UNH GeneSight coverage loss and EndoPredict divestiture.
- GAAP net loss $27.4M ($0.29 per share); adjusted EPS $0.00; adjusted EBITDA $10.3M.
- Hereditary cancer testing volume +11% YoY, revenue +3%; pharmacogenomics revenue -19% due to UnitedHealthcare coverage discontinuation.
- Gross margin 69.9%; cash and equivalents $145.4M as of Sept 30, 2025.
- Entered strategic collaboration with SOPHiA GENETICS for global liquid biopsy companion diagnostic development.

## SEC filing metadata
- accession: 0000899923-25-000103
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992325000103/0000899923-25-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992325000103/mygn-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-25-000103
- JSON: https://secwatch.observer/filing/0000899923-25-000103.json
- Plain text: https://secwatch.observer/filing/0000899923-25-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.